LONDON and PHILADELPHIA – January 20, 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, announces the appointment of Strand Hanson Limited as the Company’s Nominated Adviser, with immediate effect.
Correction to Total Voting Rights
The Company’s issued ordinary share capital is 440,415,495 Ordinary Shares. This figure may be used by holders of Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
Additional information is disclosed below under Schedule Two, paragraph (g) of the AIM Rules for Companies.